<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9875">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02978391</url>
  </required_header>
  <id_info>
    <org_study_id>NEXTBIO-631-EWD3</org_study_id>
    <nct_id>NCT02978391</nct_id>
  </id_info>
  <brief_title>UI-EWD for Endoscopic Hemostasis of Bleeding Peptic Ulcers and Bleeding After EMR/ESD</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Next Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Next Biomedical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      UI-EWD (NextBiomedical Co, Incheon, South Korea), a new hemostatic powder for endoscopic
      treatment of high-risk bleeding peptic ulcers and bleeding after ESD/EMR.

      Several endoscopic hemostasis methods are currently in use. UI-EWD (Endoscopic Wound
      Dressing) is adhesive absorbable powder as a new hemostasis material, the therapeutic effect
      and safety in endoscopic application will be verified. This study has been designed to
      observe comparing UI-EWD versus the submucosal epinephrine injection for endoscopic
      hemostasis of bleeding peptic ulcers and bleeding after EMR/ESD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent bleeding rate</measure>
    <time_frame>3 days</time_frame>
    <description>Rebleeding rate up to 3 days was obtained by clinical manifestations such as melana; decreased hemoglobin &gt; 2g/dL; hemodynamic instability or active bleeding from mucosal defect under endoscope.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>EWD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adhesive, synthetic biopolymer powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Submucosal epinephrine injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic adhesive powder</intervention_name>
    <arm_group_label>EWD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epinephrine</intervention_name>
    <arm_group_label>epinephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscopic Wound Dressing (Next Biomedical)</intervention_name>
    <arm_group_label>EWD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of bleeding peptic ulcer and active bleeding after ESD/EMR

        Exclusion Criteria:

          -  Coagulation disorder (PLT &lt; 50*10^9/L, INR &gt; 2)

          -  Connot stop taking the antiplatelet drug, NSAID, Anticoagulant drug, and Aspirin
             during endoscopic treatment and after 72h endoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-Woon Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eunhye Lee</last_name>
    <phone>82-32-858-9404</phone>
    <email>eunhye.lee@unidds.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soonchunhyang University College of Medicine</name>
      <address>
        <city>Bucheon</city>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su Jin Hong</last_name>
      <phone>82-32-621-5087</phone>
      <email>sjhong@schmc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Su Jin Hong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-Woon Shin</last_name>
      <phone>82-32-890-2548</phone>
      <email>ywshin@inha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yong-Woon Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 29, 2016</lastchanged_date>
  <firstreceived_date>November 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
